(MedPage Today) — Infants up to 6 weeks old with genetically diagnosed presymptomatic spinal muscular atrophy (SMA) treated with oral risdiplam (Evrysdi) appeared to have better functional and survival outcomes compared with a natural history…
Source link : https://www.medpagetoday.com/neurology/generalneurology/116978
Author :
Publish date : 2025-08-13 21:00:00
Copyright for syndicated content belongs to the linked Source.
